CD79B

Vincerx Pharma Presents Preclinical VIP943 and VIP924 Posters at ASH 2023

Retrieved on: 
Sunday, December 10, 2023
Toxicokinetics, Spleen, Drug, Human, Neoplasm, Survival, Lymphoid leukemia, Pharmacology, Aplastic anemia, Completeness, Spacecraft, TP53, Mitosis, CD79B, Apoptosis, Mantle cell lymphoma, Myelodysplastic syndrome, Tissue, Literature, DNA, Blood, Society, Cancer, ASH, Biochemistry, KSP, CXCR5, BCL2, CD123, Toxicity, BTK, Poster, Safety, Leukemia, Hepatotoxicity, Patient, CD19, CBC, Humanized antibody, ADC, AML, Therapy, Acute myeloid leukemia, Conjugation, MCL, Fine chemical

PALO ALTO, Calif., Dec. 10, 2023 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (Nasdaq: VINC)(“Vincerx”), a biopharmaceutical company aspiring to address the unmet medical needs of patients with cancer through paradigm-shifting therapeutics, today announced the presentation of two preclinical posters at the 65th Annual Meeting of the American Society for Hematology (ASH 2023) for VIP943, for leukemias and myelodysplastic syndrome, and VIP924, for B-cell malignancies.

Key Points: 
  • “We are excited to share new preclinical data for VIP943 and VIP94 with our stakeholders,” said Ahmed Hamdy, M.D., Chief Executive Officer of Vincerx.
  • Poster #1435: Selectivity and Safety of VIP943: A novel CD123 Targeting Antibody-Drug Conjugate (ADC) Using a Proprietary Linker and Payload Class.
  • Objective: The poster outlines a series of assays used to characterize the preclinical properties of VIP943, including biochemistry, pharmacology, on-target selectivity and activity, safety, and toxicokinetics.
  • Complete blood counts (CBCs) show that VIP924 had minimal impact on the six elements of the CBC reported in these studies.

POLIVY (Polatuzumab Vedotin-piiq) Drug Insights and Market Forecasts, 2019-2022 and 2023-2032: Focus on 7MM - United States, Germany, France, Italy, Spain, United Kingdom, and Japan - ResearchAndMarkets.com

Retrieved on: 
Friday, December 15, 2023
Biotechnology, General Health, Pharmaceutical, Health, MMAE, Apoptosis, Research, Immunoglobulin G, ADC, Clinical trial, SWOT, EU4, Microtubule, Polatuzumab vedotin, Roche, CD79B, Cell division, NHL, Fine chemical, Risk management, Vaccine, Pharmaceutical industry, DLBCL

This report provides comprehensive insights about POLIVY for Diffuse Large B-cell lymphoma (DLBCL) in the seven major markets.

Key Points: 
  • This report provides comprehensive insights about POLIVY for Diffuse Large B-cell lymphoma (DLBCL) in the seven major markets.
  • The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities.
  • Further, it also consists of future market assessments inclusive of the POLIVY market forecast analysis for DLBCL in the 7MM, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in DLBCL.
  • What are the other emerging products available and how are these giving competition to POLIVY for DLBCL?

Nurix Therapeutics Presents Data from Studies of Its Targeted Protein Degraders in B Cell Malignancies and Initiates Expansion of NX-2127 Phase 1b Trial in Diffuse Large B Cell Lymphoma and Mantle Cell Lymphoma Indications

Retrieved on: 
Wednesday, June 14, 2023
Lymphoma, CD79B, Central nervous system, University, PD, Chronic lymphocytic leukemia, Cytarabine, SC1, Follicular lymphoma, Lymphoid leukemia, Half-life, DLBCL, Hematology, ICML, IMCL, Non-Hodgkin lymphoma, Survival, Pharmacokinetics, Head, Absorption, BTK, CNS, Etoposide, International Conference on Emerging Infectious Diseases, Primary central nervous system lymphoma, Patient, UCSF, American Society of Hematology, Mantle cell lymphoma, SAN, Memorial Sloan Kettering Cancer Center, AUC, Mouse, Bone marrow, MCL, Therapy, Poster, Society, Conference, Safety, Vaccine, Pharmaceutical industry, Cmax

SAN FRANCISCO, June 14, 2023 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with hematologic malignancies and solid tumors, today announced the presentation of clinical and preclinical data from its targeted protein degradation programs, NX-5948 and NX-2127, which are being evaluated in ongoing Phase 1 clinical trials in patients with relapsed/refractory B cell malignancies. These data are being presented at the 17th International Conference on Malignant Lymphoma (ICML) which is being held June 13-17, in Lugano, Switzerland.

Key Points: 
  • These data are being presented at the 17th International Conference on Malignant Lymphoma (ICML) which is being held June 13-17, in Lugano, Switzerland.
  • Limitations of current covalent and non-covalent BTK inhibitors include the susceptibility to mutational escape as a basis for resistance.
  • Nurix’s BTK degraders have the potential to address these limitations of BTK inhibitors and provide a new therapeutic option for patients.
  • Nurix is announcing plans to initiate two new Phase 1b dose expansion cohorts in the ongoing Phase 1a/1b clinical trial of NX-2127 in patients with relapsed or refractory B-cell malignancies.

Genentech Presents New and Updated Data for Polivy in Previously Untreated Diffuse Large B-Cell Lymphoma at ASH 2022

Retrieved on: 
Sunday, December 11, 2022
Research, Hospitals, Genetics, Clinical Trials, Biotechnology, General Health, Pharmaceutical, Health, Science, Oncology, Liver, Phase, Pain scale, Society, Rituximab, NHL, B-cell lymphoma, Lymphoma, Patient, ROG, Pharmacokinetics, Risk, DLBCL, Rash, Skin, Prednisone, Doxorubicin, RO, ADC, Death, Fatigue, Muscle weakness, Pain, Abdomen, Vincristine, Quality of life (healthcare), Tumor lysis syndrome, Infection, Dizziness, Confusion, Food, CD79B, Chills, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Cough, Oxaliplatin, Diarrhea, PFS, Overalls, Urination, ASH, Exposition, Arm, Salvage therapy, Nausea, Progression-free survival, Vomiting, Weight loss, Survival, Safety, Hoffmann-La Roche, Walking, Fever, Cyclophosphamide, Fine chemical, Pharmaceutical industry, Medical device, Vaccine, Genentech, Polatuzumab vedotin, EU

Data from the POLARIX study support the potential benefit of Polivy in combination with Rituxan (rituximab), cyclophosphamide, doxorubicin and prednisone (R-CHP) to improve outcomes for people with previously untreated diffuse large B-cell lymphoma (DLBCL).

Key Points: 
  • Data from the POLARIX study support the potential benefit of Polivy in combination with Rituxan (rituximab), cyclophosphamide, doxorubicin and prednisone (R-CHP) to improve outcomes for people with previously untreated diffuse large B-cell lymphoma (DLBCL).
  • Too many patients with diffuse large B-cell lymphoma see their cancer relapse or progress after initial treatment.
  • These updated POLARIX data indicate the potential benefits that this Polivy based-regimen could bring to people living with this aggressive type of lymphoma, and demonstrate our commitment to developing new treatment options.
  • Diffuse large B-cell lymphoma (DLBCL) is the most common form of non-Hodgkins lymphoma (NHL), accounting for about one in three cases of NHL.

FDA Grants Priority Review to Genentech’s Mosunetuzumab for People With Relapsed or Refractory Follicular Lymphoma

Retrieved on: 
Wednesday, July 6, 2022
Oncology, FDA, Health, Clinical Trials, Pharmaceutical, Biotechnology, Diagnosis, ROG, Fever, Liver, RO, Muscle weakness, Hypophosphatemia, Progression-free survival, Vomiting, Food, Headache, Dizziness, Lists of diseases, Fatigue, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Confusion, CD20, Lymphatic system, FDA, Patient, Pain scale, Weight loss, Lenalidomide, BTD, Mark (given name), Follicular lymphoma, B-cell lymphoma, AES, Pharmacokinetics, Cytokine release syndrome, Clinical trial, Diarrhea, Collection, DLBCL, Hoffmann-La Roche, European Commission, ASH, Walking, Rash, Urination, CD79B, AE, Neutropenia, CR, Infection, Cough, Nausea, Review, Priority review, ADC, Chills, Abdomen, Disease, Pain, Tumor lysis syndrome, Prognosis, Risk, CD3, NHL, Skin, Safety, Society, BLA, Pharmaceutical industry, Medical device, Vaccine, Polatuzumab vedotin, Genentech

The FDA is expected to make a decision on approval of this novel cancer immunotherapy by December 29, 2022.

Key Points: 
  • The FDA is expected to make a decision on approval of this novel cancer immunotherapy by December 29, 2022.
  • New therapeutic options are needed for follicular lymphoma, which often relapses after initial therapy and becomes increasingly difficult to treat each time it returns.
  • The GO29781 study [ NCT02500407 ] is a Phase I/II, multicenter, open-label, dose-escalation and expansion study evaluating the safety, efficacy and pharmacokinetics of mosunetuzumab in people with relapsed or refractory B-cell non-Hodgkins lymphoma.
  • Follicular lymphoma (FL) is the most common slow-growing (indolent) form of non-Hodgkins lymphoma, accounting for about one in five cases.

Calithera Biosciences Announces First Patient Enrolled in Phase 2 Clinical Trial of Mivavotinib in Relapsed/Refractory non-GCB (ABC) Diffuse Large B-Cell Lymphoma

Retrieved on: 
Thursday, June 23, 2022
GLOBE, SYK, B-cell lymphoma, Patient, Progression-free survival, Safety, Security (finance), Private Securities Litigation Reform Act, MYD88, CD79, Failure, Neoplasm, CALA, GCB, Nasdaq, SAN, Cancer, ABC, Doctor of Philosophy, U.S. Securities and Exchange Commission, Population, Risk, NGS, CD79B, Pharmaceutical industry, Medical imaging, DLBCL

SOUTH SAN FRANCISCO, Calif., June 23, 2022 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage, precision-oncology biopharmaceutical company, announced that the first patient has been enrolled in a multicenter phase 2 clinical trial evaluating its spleen tyrosine kinase (SYK) inhibitor mivavotinib (CB-659) in patients with relapsed/refractory non-germinal center B-cell like (non-GCB) diffuse large B-cell lymphoma (DLBCL), a DLBCL subpopulation that primarily comprises patients with activated B-cell like disease (ABC).

Key Points: 
  • The phase 2 clinical trial ( NCT05319028 ) is an open-label study of mivavotinib monotherapy in patients with relapsed/refractory non-GCB DLBCL.
  • Data from the trial could position Calithera to initiate a study with registrational intent in biomarker-specific DLBCL populations.
  • Calithera Biosciences is a clinical-stage, precision oncology biopharmaceutical company developing targeted therapies to redefine treatment for biomarker-specific patient populations.
  • In addition, clinical trials may not confirm any safety, potency or other product characteristics described or assumed in this press release.

Calithera Biosciences Reports First Quarter 2022 Financial Results and Recent Highlights

Retrieved on: 
Tuesday, May 10, 2022
U.S. Securities and Exchange Commission, Population, CD79, Private Securities Litigation Reform Act, Nasdaq, DLBC, GLOBE, American Association for Cancer Research, Neoplasm, Safety, Research, Common stock, NGS, Patient, Security (finance), Doctor of Philosophy, Association, Webcast, Risk, CD79B, American Association, Cancer, SYK, ABC, NSCLC, NFE2L2, CALA, Conference, ID, AACR, MYD88, Protein, SAN, Annual general meeting, Investor, Communications satellite, Pharmaceutical industry, Medical imaging, DLBCL, VPS4A, NRF2, VPS4B

SOUTH SAN FRANCISCO, Calif., May 10, 2022 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage, precision-oncology biopharmaceutical company, today announced its financial results for the first quarter ended March 31, 2022.

Key Points: 
  • ET on Tuesday, May 10, 2022 --
    SOUTH SAN FRANCISCO, Calif., May 10, 2022 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage, precision-oncology biopharmaceutical company, today announced its financial results for the first quarter ended March 31, 2022.
  • We made significant headway in the transfer of mivavotinib and sapanisertib materials to Calithera during the first quarter and are well into site start-up activities.
  • Calithera anticipates the first patient enrolled in the second quarter of 2022.
  • Calithera anticipates the first patient enrolled in this study in the second quarter of 2022.

Araris Biotech AG Presents Preclinical Data Highlighting Anti-CD79b ADC Program and Late-Breaking Data on Nectin-4 ADC at the American Association for Cancer Research (AACR) 2022 Annual Meeting

Retrieved on: 
Friday, April 8, 2022
CD79B, DAR, EV, ADC, AACR, CDT, Research, Paul Scherrer Institute, Half-life, Therapeutic index, American Association, PSI, Senior, Entrepreneurship, Association, Technology, Control, Annual general meeting, American Association for Cancer Research, ETH Zurich, GLOBE, Animal, FDA, Translational research, MMAE, Fine chemical, Vaccine

We are looking forward to studying our linker technology further and continuing to advance our anti-CD79b antibody candidate.

Key Points: 
  • We are looking forward to studying our linker technology further and continuing to advance our anti-CD79b antibody candidate.
  • The poster number is 25 and will be presented by Isabella Attinger-Toller, Ph.D., Co-Founder, Senior VP of Translational Research.
  • Araris Biotech AG is pioneering the development of its novel antibody-drug conjugate (ADC)-linker technology to enable efficient and precise production of ADCs.
  • Araris is a spin-off company from the Paul Scherrer Institute (PSI) and ETH Zurich.

US Oncology Research, The US Oncology Network and Ontada Announce Data Presentations Across Areas of Critical Need at 2021 American Society of Hematology Annual Meeting and Exposition

Retrieved on: 
Thursday, December 9, 2021
Oncology, Health, Research, Pharmaceutical, Science, Biotechnology, Health, Technology, McKesson Corporation, Exposition, Rituximab, Safety, Polatuzumab vedotin, Network, Lenalidomide, FACOG, Physician, FACS, Umbralisib, Prednisone, Lymphoma, Research, CD79B, Multiple myeloma, Interview, Community, Observational study, B-cell lymphoma, Malignancy, Non-Hodgkin lymphoma, Bone marrow, Cancer, FDA, Society, ASH, Relapse, Proteasome inhibitor, The Network, Lymphatic system, ET, Science, Education, DLBCL, Hematology, Prognosis, MM, Medical imaging, Fine chemical, Pharmaceutical industry, Medicine, US Oncology Research, The US Oncology Network, Ontada, US ONCOLOGY RESEARCH, THE US ONCOLOGY NETWORK, ONTADA

The ASH Annual Meeting, a leading scientific event in malignant and non-malignant hematology, will take place in Atlanta, Georgia and virtually from Dec. 11-14, 2021.

Key Points: 
  • The ASH Annual Meeting, a leading scientific event in malignant and non-malignant hematology, will take place in Atlanta, Georgia and virtually from Dec. 11-14, 2021.
  • However, there is still need for advances, said Robert L. Coleman, MD, FACOG, FACS, chief scientific officer, US Oncology Research.
  • Ontada is an oncology real-world data and evidence, clinical education and provider technology business dedicated to improving the lives of cancer patients.
  • US Oncology Research draws from a network of experienced investigators and dedicated clinical staff who specialize in oncology clinical trials.

Provention Bio Appoints Jan Hillson, M.D., as Senior Vice President of Clinical Development

Retrieved on: 
Wednesday, November 17, 2021
Stanford University School of Medicine, Patient, Senior, Virginia, Degenerative disease, Environmental engineering, M281, Disclosure, Biophysical environment, Security (finance), Lists of diseases, Safety, Risk, Industry, Scripps Institution of Oceanography, BANK, CD32B, DART, Company, News, Virginia Mason Medical Center, Bristol Myers Squibb, Clinical trial, University, Regulation, U.S. Securities and Exchange Commission, Ocean, Lupus, University of Washington Department of Bioengineering, COVID-19, California Institute for Quantitative Biosciences, California, Nasdaq, Twitter, CD79B, Drug, Health, Bio, ANCA, Michigan State University, Assistant, RED, Harvard Medical School, Education, Growth, ZymoGenetics, Translation, Pharmaceutical industry

RED BANK, N.J., Nov. 17, 2021 /PRNewswire/ --Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, today announced the appointment of Jan Hillson, M.D., as Senior Vice President of Clinical Development.

Key Points: 
  • RED BANK, N.J., Nov. 17, 2021 /PRNewswire/ --Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, today announced the appointment of Jan Hillson, M.D., as Senior Vice President of Clinical Development.
  • Dr. Hillson was most recently Senior Vice President, Clinical Development at Alpine Immune Sciences.
  • Dr. Hillson also served as Senior Vice Presidentof Clinical and Translational Research at ChemoCentryx.
  • As with any pharmaceutical under development, there are significant risks in the development, regulatory approval and commercialization of new products.